← Back to Screener
Prestige Consumer Healthcare Inc. (PBH)
Price$57.05
Favorite Metrics
Price vs S&P 500 (26W)-13.02%
Price vs S&P 500 (4W)-11.06%
Market Capitalization$2.72B
P/E Ratio (Annual)12.69x
All Metrics
P/CF (Annual)10.83x
Book Value / Share (Quarterly)$38.66
Revenue Growth (3Y)1.54%
Cash Flow / Share (Quarterly)$5.65
Price vs S&P 500 (YTD)-9.32%
Gross Margin (TTM)56.12%
Net Profit Margin (TTM)16.90%
EPS (TTM)$3.78
10-Day Avg Trading Volume0.66M
EPS Excl Extra (TTM)$3.78
Revenue Growth (5Y)3.39%
EPS (Annual)$4.29
ROI (Annual)7.53%
Gross Margin (Annual)55.76%
Net Profit Margin (5Y Avg)13.30%
Cash / Share (Quarterly)$1.32
P/E Basic Excl Extra (TTM)14.61x
Revenue Growth QoQ (YoY)-2.37%
EPS Growth (5Y)9.00%
P/E Normalized (Annual)12.69x
ROA (Last FY)6.31%
Revenue Growth TTM (YoY)-1.31%
EBITD / Share (TTM)$6.67
ROE (5Y Avg)8.76%
Operating Margin (TTM)29.21%
Cash Flow / Share (Annual)$4.91
P/B Ratio1.49x
P/B Ratio (Quarterly)1.62x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)3.37x
Net Interest Coverage (TTM)6.97x
ROA (TTM)5.42%
EPS Growth QoQ (YoY)-20.45%
EV / EBITDA (TTM)11.30x
EPS Incl Extra (Annual)$4.29
Current Ratio (Annual)4.20x
Quick Ratio (Quarterly)1.81x
3-Month Avg Trading Volume0.45M
52-Week Price Return-29.90%
EV / Free Cash Flow (Annual)15.28x
P/E Incl Extra (TTM)14.61x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$-26.59
P/S Ratio (Annual)2.39x
Asset Turnover (Annual)0.33x
52-Week High$89.37
Operating Margin (5Y Avg)23.68%
EPS Excl Extra (Annual)$4.29
CapEx CAGR (5Y)-13.82%
26-Week Price Return-9.04%
Quick Ratio (Annual)2.74x
13-Week Price Return-11.84%
Total Debt / Equity (Annual)0.55x
Current Ratio (Quarterly)3.11x
Enterprise Value$3,716.579
Revenue / Share Growth (5Y)3.81%
Asset Turnover (TTM)0.32x
Book Value / Share Growth (5Y)9.66%
Revenue / Employee (Annual)$2
Inventory Turnover (Annual)3.51x
Pretax Margin (Annual)24.98%
Cash / Share (Annual)$1.98
3-Month Return Std Dev33.24%
Gross Margin (5Y Avg)56.37%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)2.49%
EBITDA Interim CAGR (5Y)-0.55%
ROE (Last FY)11.70%
Net Interest Coverage (Annual)7.40x
EPS Basic Excl Extra (Annual)$4.29
P/FCF (TTM)10.20x
Receivables Turnover (TTM)6.17x
EV / Free Cash Flow (TTM)13.91x
Total Debt / Equity (Quarterly)0.58x
EPS Incl Extra (TTM)$3.78
Receivables Turnover (Annual)6.13x
ROI (TTM)6.52%
P/S Ratio (TTM)2.47x
Pretax Margin (5Y Avg)17.39%
Revenue / Share (Annual)$22.72
Tangible BV / Share (Annual)$-28.62
Forward P/E12.57x
Free OCF CAGR (5Y)4.02%
Price vs S&P 500 (52W)-59.73%
P/E Ratio (TTM)14.61x
EPS Growth TTM (YoY)-11.39%
Year-to-Date Return-6.68%
5-Day Price Return1.43%
EPS Normalized (Annual)$4.29
ROA (5Y Avg)4.11%
Net Profit Margin (Annual)18.86%
Month-to-Date Return-2.87%
Cash Flow / Share (TTM)$-1.01
EBITD / Share (Annual)$7.05
EPS Growth (3Y)1.99%
Operating Margin (Annual)29.60%
LT Debt / Equity (Annual)0.54x
P/CF (TTM)9.85x
ROI (5Y Avg)4.92%
P/E Excl Extra (TTM)14.61x
LT Debt / Equity (Quarterly)0.56x
EPS Basic Excl Extra (TTM)$3.78
P/B Ratio (Annual)2.32x
Inventory Turnover (TTM)3.07x
Pretax Margin (TTM)24.16%
Book Value / Share (Annual)$37.06
Price vs S&P 500 (13W)-12.53%
Net Margin Growth (5Y)5.00%
Beta0.45x
P/FCF (Annual)11.20x
Revenue / Share (TTM)$22.95
ROE (TTM)10.16%
52-Week Low$51.24
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.20
4.20
4.20
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PBHPrestige Consumer Healthcare Inc. | 2.47x | -1.31% | 56.12% | 9.00% | $57.05 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Prestige Consumer Healthcare is a leading pure-play OTC healthcare provider with a portfolio of category-dominant brands including Clear Eyes, Dramamine, Monistat, and Summer's Eve. These brands maintain strong market positions backed by healthcare professional endorsements. The company generates approximately 85% of revenue from North America, with the remainder from Australia, New Zealand, and select Asian markets.